ECSP22093652A - Compuestos de imidazopiridazina y usos de los mismos - Google Patents

Compuestos de imidazopiridazina y usos de los mismos

Info

Publication number
ECSP22093652A
ECSP22093652A ECSENADI202293652A ECDI202293652A ECSP22093652A EC SP22093652 A ECSP22093652 A EC SP22093652A EC SENADI202293652 A ECSENADI202293652 A EC SENADI202293652A EC DI202293652 A ECDI202293652 A EC DI202293652A EC SP22093652 A ECSP22093652 A EC SP22093652A
Authority
EC
Ecuador
Prior art keywords
compounds
imidazopyridazine compounds
imidazopyridazine
alk2 activity
cancer
Prior art date
Application number
ECSENADI202293652A
Other languages
English (en)
Inventor
Jun Pan
Liangxing Wu
Wenqing Yao
Yu Bai
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of ECSP22093652A publication Critical patent/ECSP22093652A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Dental Preparations (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de Fórmula (I), métodos de uso de los compuestos para inhibir la actividad de ALK2 y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos son útiles para tratar, prevenir o mejorar enfermedades o trastornos asociados con la actividad de ALK2, tales como el cáncer.
ECSENADI202293652A 2020-06-12 2022-12-09 Compuestos de imidazopiridazina y usos de los mismos ECSP22093652A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063038410P 2020-06-12 2020-06-12

Publications (1)

Publication Number Publication Date
ECSP22093652A true ECSP22093652A (es) 2023-02-28

Family

ID=76971994

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202293652A ECSP22093652A (es) 2020-06-12 2022-12-09 Compuestos de imidazopiridazina y usos de los mismos

Country Status (17)

Country Link
US (2) US11840546B2 (es)
EP (1) EP4165051A1 (es)
JP (1) JP2023530088A (es)
KR (1) KR20230025434A (es)
CN (1) CN115956081A (es)
AR (1) AR122587A1 (es)
AU (1) AU2021288107A1 (es)
BR (1) BR112022025191A2 (es)
CA (1) CA3184811A1 (es)
CL (1) CL2022003453A1 (es)
CO (1) CO2022017969A2 (es)
EC (1) ECSP22093652A (es)
IL (1) IL298248A (es)
MX (1) MX2022015493A (es)
PE (1) PE20230491A1 (es)
TW (1) TWI895442B (es)
WO (1) WO2021252781A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210116488A (ko) 2018-12-20 2021-09-27 인사이트 코포레이션 액티빈 수용체-유사 키나제-2의 억제제로서의 이미다조피리다진 및 이미다조피리딘 화합물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60105023T2 (de) 2000-06-28 2005-08-18 Smithkline Beecham P.L.C., Brentford Nassvermahlungsverfahren
ATE522249T1 (de) * 2007-07-26 2011-09-15 Novartis Ag Organische verbindungen
JP5456681B2 (ja) 2007-10-17 2014-04-02 ノバルティス アーゲー ＡＬＫ阻害剤として有用なイミダゾ［１，２−ａ］ピリジン誘導体
CA2806655A1 (en) 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2705037B1 (de) 2011-05-06 2016-06-22 Bayer Intellectual Property GmbH Substituierte imidazopyridine und imidazopyridazine und ihre verwendung
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
AU2016358100B2 (en) 2015-11-19 2021-05-27 Incyte Corporation Heterocyclic compounds as immunomodulators
TW201726623A (zh) 2015-12-17 2017-08-01 英塞特公司 作為免疫調節劑之雜環化合物
TWI850624B (zh) 2015-12-22 2024-08-01 美商英塞特公司 作為免疫調節劑之雜環化合物
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
DK3472167T3 (da) 2016-06-20 2022-09-05 Incyte Corp Heterocykliske forbindelser som immunomodulatorer
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
US20190218214A1 (en) 2016-09-14 2019-07-18 Vanderbilt University Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof
MX2019002951A (es) 2016-09-15 2019-09-11 Armstrong World Ind Inc Sistema de techo con movimiento aereo.
IL295660A (en) 2016-12-22 2022-10-01 Incyte Corp Benzooxazole derivatives as immunomodulators
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
ES2929193T3 (es) 2016-12-22 2022-11-25 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de la internalización de PD-L1
JP2020511424A (ja) * 2017-01-18 2020-04-16 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害としての縮合複素環式化合物
WO2018165569A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Therapeutic compounds and methods
KR20210116488A (ko) 2018-12-20 2021-09-27 인사이트 코포레이션 액티빈 수용체-유사 키나제-2의 억제제로서의 이미다조피리다진 및 이미다조피리딘 화합물

Also Published As

Publication number Publication date
CN115956081A (zh) 2023-04-11
US11840546B2 (en) 2023-12-12
EP4165051A1 (en) 2023-04-19
CO2022017969A2 (es) 2023-02-27
PE20230491A1 (es) 2023-03-23
TWI895442B (zh) 2025-09-01
KR20230025434A (ko) 2023-02-21
US20210388003A1 (en) 2021-12-16
TW202214660A (zh) 2022-04-16
BR112022025191A2 (pt) 2023-03-07
MX2022015493A (es) 2023-03-21
CA3184811A1 (en) 2021-12-16
CL2022003453A1 (es) 2023-05-26
IL298248A (en) 2023-01-01
JP2023530088A (ja) 2023-07-13
WO2021252781A1 (en) 2021-12-16
US20240083918A1 (en) 2024-03-14
AU2021288107A1 (en) 2022-12-15
AR122587A1 (es) 2022-09-21

Similar Documents

Publication Publication Date Title
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
ECSP24035717A (es) Compuestos de quinolina como inhibidores de kras
CO2022010241A2 (es) Inhibidores de sos1
DOP2025000264A (es) Inhibidores de kras de 2-azabiciclo [2.2.1] heptano
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
CL2024003450A1 (es) Compuestos y usos de estos
CO2022016899A2 (es) Moduladores de il-17a
MX2022013396A (es) Compuestos de tetrahidroisoquinolina como activadores de nrf2.
CL2023000061A1 (es) Macrociclos y su uso
AR128109A1 (es) Spiros y análogos relacionados para inhibir yap / taz-tead
CL2024002532A1 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
CL2024003731A1 (es) Compuestos tricíclicos de triazolo, inhibidores de dgk; uso para tratar cáncer.
MX2022013398A (es) Compuestos de tetrahidroisoquinolina como activadores de nrf2.
ECSP22093652A (es) Compuestos de imidazopiridazina y usos de los mismos
MX2024008413A (es) Compuestos macrocíclicos y uso como inhibidores de cinasas.
AR126389A1 (es) Compuestos tricíclicos como inhibidores de kras
AR117459A1 (es) Imidazopiridina y compuestos de imidazopiridazina y usos de los mismos
AR132459A1 (es) Inhibidores de kras de pirrolidina
MX2023007297A (es) 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1.
MX2024009743A (es) Analogos de tofa, preparaciones para la reduccion del sebo con un contenido de tales analogos y el uso cosmetico y/o terapeutico de tales analogos como principio eficaz para la reduccion o prevencion del sebo
AR134259A1 (es) Compuestos de pirimidina bicíclicos, métodos y usos de estos
EA202191738A1 (ru) Соединения имидазопиридазина и имидазопиридина и их применение